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The urological community has for decades pursued 
studies of so-called oﬀ -label drugs—ie, pharmaceutical 
agents used for an unapproved or unintended 
indication—for treatment of urolithiasis. But perhaps 
urologists should question why the pharmaceutical 
industry has not expressed an interest in drug 
development for this indication. Most urologists might 
have never even thought about the consequences, 
secondary eﬀ ects, or possible (serious) adverse events 
that can occur during oﬀ -label use of a drug. However, 
the reason why urologists feel comfortable using 
α blockers for the treatment of urinary stones, for 
example, could be that both the American Urological 
Association and European Association of Urology 
guidelines include α blockers in their treatment 
recommendations.1,2
Use of α blockers to facilitate stone passage has 
increased in popularity, even though eﬃ  cacy has only 
been supported by level 2a evidence. In the absence of 
a methodologically good and well powered randomised 
controlled trial (RCT), clinicians often have to turn 
to evidence from less reliable sources, such as single-
centre comparative studies, registries with matching 
groups, non-placebo-controlled or unpowered RCTs,3 
and (as a last resort) meta-analyses.4 Sophisticated 
statistical tests are also needed to assist what should be 
straightforward analyses.
In The Lancet, Robert Pickard and colleagues5 present 
the results of their three-group, randomised, placebo-
controlled trial of medical expulsive therapy (tamsulosin 
400 μg or nifedipine 30 mg) in adults with ureteric colic. 
1167 patients were randomly assigned, and in terms of 
the trial’s primary endpoint—the proportion of patients 
not needing further intervention for stone clearance 
within 4 weeks—no diﬀ erence was reported between 
treatment groups (303 [80%] of 379 participants in 
the placebo group did not require further intervention, 
compared with 307 [81%] of 378 participants in the 
tamsulosin group [adjusted risk diﬀ erence 1·3%, 
95% CI –5·7 to 8·3] and 304 [80%] of 379 participants 
in the nifedipine group [0·5%, –5·6 to 6·5]). This study 
therefore removes, beyond any reasonable doubt, any 
positive expectations with respect to α blockers in the 
treatment of ureter stones. Furthermore, because the 
trial had three treatment groups, the ﬁ ndings eliminate 
doubt about whether one active drug might be more 
powerful than the other.
Several things can be learned from Pickard and 
colleagues’ study5 and its ﬁ ndings—the main one 
being the important role of quality of evidence and 
reporting of outcomes. It raises the question of 
whether well powered RCTs are indeed the ultimate 
way to prove eﬃ  cacy of a speciﬁ c treatment. Taking 
the accompanying study as an example, the answer 
is indisputably yes. When planning such a trial, the 
investigators have to obtain insight from case series 
or registries, but deﬁ nitive evidence must come from 
RCTs. A power calculation is a prerequisite of any well 
designed RCT, but was either missed or not reported in 
a recently published RCT on ureteral stones.6 Either by 
omission or absence, the lack of properly undertaken or 
reported methods raises concerns about the usefulness 
of the data, and might lead to incorrect conclusions. 
Simply put, the evidence in all studies other than 
properly designed and powered RCTs is just not robust 
enough to use as the basis for treatment decisions.
The collection and reporting of evidence comes with 
responsibilities, and urological societies are likely to be 
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In the USA, as in many other settings, the main 
societal response to the harms of opioid addiction is 
arrest and imprisonment. The so-called war on drugs 
has contributed to an era of mass incarceration, in 
which about one in every 100 US citizens, almost all 
poor, many from racial minority groups and many 
who use illicit drugs, are currently detained in jails or 
prisons.1 The USA not only has the world’s highest 
rate of incarceration, but treats opioid-addicted 
prisoners very diﬀ erently from those in prisons in other 
countries. Unlike other serious chronic conditions 
such as cancer, diabetes, or HIV/AIDS, individuals with 
opioid dependence will often have their medically 
eﬀ ective treatment—such as methadone, the standard 
Withdrawal from methadone in US prisons: cruel and unusual?
instrumental in improving the process. Encouragingly, 
the Endourological Society has created the Clinical 
Research Oﬃ  ce of the Endourological Society (CROES).7 
Through the global network of CROES, several registries 
have been started, followed by large-scale RCTs.8,9 The 
conclusions from these studies emphasise that the 
responsibility to provide reliable evidence requires input 
from stakeholders in urology, industry, and regulatory 
agencies around the world.
But other lessons too can be learned from Pickard and 
colleagues’ study. Even in a well designed and undertaken 
trial, investigators need to improve standardisation of 
patient outcome reporting. Although attempts have 
been made to improve reporting of clinical research, 
international standards to deﬁ ne patient outcomes 
are limited.10,11 Opondo and colleagues12 were the ﬁ rst 
to propose recommendations to deﬁ ne outcomes in 
patients treated for renal stones. Standardised reporting 
of outcomes is the ﬁ rst step towards improving scientiﬁ c 
knowledge; it forms the basis for comparison between 
and among studies, and ultimately should allow for 
meaningful systematic reviews and meta-analyses.
The primary outcome in Pickard and colleagues’ study 
was the proportion of participants in each group who 
did not need further intervention for stone clearance 
within 4 weeks of randomisation. Although this 
outcome is possibly clinically relevant, the question 
arises as to whether ﬁ ndings would have been the same 
if the primary outcome of the study had been conﬁ rmed 
stone expulsion or absence of a stone on imaging. 
To help compare results between diﬀ erent studies, 
outcomes should be deﬁ ned and the same deﬁ nitions 
used across diﬀ erent studies.
Critical appraisal of research methods and ﬁ ndings 
is a demanding task for urologists to undertake when 
deciding on the best treatment for their patients, but it 
is very rewarding when successful. A thoughtful research 
process, involving formulation of a meaningful research 
question and proper methodology, reporting, and 
critical appraisal, will ultimately allow the best quality of 
care to be delivered to patients.
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